Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Aptalis Pharma
ClinicalTrials.gov Identifier:
NCT00408317
First received: December 4, 2006
Last updated: January 27, 2014
Last verified: January 2014

December 4, 2006
January 27, 2014
November 2006
April 2007   (final data collection date for primary outcome measure)
Percent Coefficient of Fat Absorption (CFA) [ Time Frame: Day 3 to Day 7 in first intervention period and second intervention period ] [ Designated as safety issue: No ]
Percent (%) CFA was calculated as ([fat intake - fat excretion]/fat intake)*100, determined by the stools collected during the 72-hour period which could extend to 96 hours during both intervention periods. Mean CFA percent was calculated for 72-hour/96-hour period during Day 3 to Day 7 in the first and second intervention periods.
Compare the coefficient of fat absorption (CFA) of ULTRASE MT20 to placebo. The CFA will be measured by assessing the dietary fat intake and excretion during a 72-hour period.
Complete list of historical versions of study NCT00408317 on ClinicalTrials.gov Archive Site
Percent Coefficient of Nitrogen Absorption (CNA) [ Time Frame: Day 3 to Day 7 in first intervention period and second intervention period ] [ Designated as safety issue: No ]
Percent (%) CNA was calculated as [(nitrogen intake-nitrogen excretion)/nitrogen intake]*100, determined by the stools collected during the 72-hour period which could extend to 96 hours during both intervention periods. Nitrogen intake was calculated as protein intake/6.25. Mean percent CNA was calculated for 72-hour/96-hour period during Day 3 to Day 7 in the first and second intervention periods.
Compare the coefficient of protein absorption (CNA) of ULTRASE MT20 to placebo. The CNA will be measured as the CFA. The safety will be evaluated from the laboratory analyses, the adverse events and the overall signs and symptoms.
  • Number of Bowel Movements [ Time Frame: Day 3 on first intervention period and second intervention period ] [ Designated as safety issue: No ]
    Number of bowel movements of each participant was calculated from frequency of stools by the participant per day. Mean daily number of bowel movements on Day 3 for the first treatment period and second treatment period was summarized.
  • Percentage of Stool Categorized by Consistency [ Time Frame: Day 4 on first intervention period and second intervention period ] [ Designated as safety issue: No ]
    Stool consistency was categorized as hard, formed/normal, soft or watery stool. Percentage of stools of a specific consistency of each participant was calculated as the number of stools with a specific consistency relative to the total number of stools during the collection period. Mean percentage of stool with specific consistency on Day 4 for the first treatment period and second treatment period period for total participants was summarized.
Not Provided
 
Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)
A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase® MT20 to Placebo for the Correction of Steatorrhea in Patients With Cystic Fibrosis (CF)

The purpose of this study is to assess the safety and efficacy of Ultrase® MT20 compared to placebo for the correction of fat and protein malabsorption in participants with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI). This study is sponsored by Aptalis Pharma (formerly Axcan).

This is a Phase III, multicenter, randomized, double-blind, two-period cross-over, placebo-controlled study designed to compare the efficacy and safety of Ultrase® MT20 to placebo in participants with CF and pancreatic insufficiency. The study consists of a screening period (up to 11 days) and two treatment periods (6-7 days). During screening period participants will be treated with open-label Ultrase® MT18 or MT20. Each treatment period will be preceded by a stabilization period (4 days) and the two treatment periods are separated by a break period (3-6 days). A safety follow-up visit will be performed 7-10 days after discharge from the last treatment period .

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • Cystic Fibrosis
  • Exocrine Pancreatic Insufficiency
  • Drug: Ultrase® MT20
    Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
    Other Name: Pancreatic enzyme product
  • Drug: Placebo
    Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
  • Experimental: Ultrase® MT20
    Intervention: Drug: Ultrase® MT20
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
April 2007
April 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participants or their legally authorized representative must understand the nature of the study and sign an informed consent or assent form along with a parental form
  • Participants must have a confirmed diagnosis of CF based on 1 or more clinical features consistent with the CF phenotype, and one of the following:

    • A genotype with 2 identifiable mutations consistent with CF
    • A sweat chloride test greater than 60 millimole per liter (mmol/L) by quantitative pilocarpine iontophoresis
  • Participants must have PI as demonstrated by a fecal elastase-1 (FE-1) concentration less than 100 microgram per gram (mcg/g) of stools (ScheBo test) and must require pancreatic enzyme supplementation
  • Participants must be clinically stable as evidenced by medical and medication history, baseline physical examination including vital signs and laboratory analyses
  • Participants must be 7 years and older
  • Participants must have an adequate nutritional status based on the following body mass index (BMI):

    • Participants 7 to 20 years old must have a BMI greater than or equal to fifth percentile
    • Female participants greater than 20 years old must have a BMI greater than or equal to 16
    • Male participants greater 20 years old must have a BMI greater than or equal to 16.5
  • Participants must be on an optimal clinical dose of pancreatic enzymes (Ultrase® MT18 or MT20 or other pancreatic enzymes preparations including Ultrase® MT12) prior to entry in the study, and must tolerate this medication in the opinion of the investigator
  • Participants must be able to swallow capsules and must be able to eat a high fat diet calculated as 2 gram (± 15%) fat per kilogram body weight per day
  • Participants must be, in the opinion of the investigator, able and willing to complete this study
  • Female participants must be premenarcheal, surgically sterile or postmenopausal for at least 12 consecutive months. Otherwise, the women of childbearing potential (WOCBP) must not be pregnant and must have practiced an acceptable method of contraception for at least one month prior to the study entry

Exclusion Criteria:

  • Participants with a known contraindication, sensitivity or hypersensitivity to Ultrase or any porcine protein
  • Participants with a known allergy to the food drug and cosmetic (FD&C) Blue No. 2 dye indicator (stool marker)
  • Participants not willing to stop the prohibited medications or products at study entry and throughout the study
  • Participants who are using narcotics
  • Participants who are using bowel stimulants and/or laxatives on a regular basis
  • Participants with acute pancreatitis or acute exacerbation of chronic pancreatic disease
  • Participants with an acute pulmonary infection
  • Participants with a history of bowel resection
  • Participants suffering from any dysmotility disorders
  • Participants with chronic or severe abdominal pain
  • Participants receiving enteral tube feeding and not willing to stop during the course of the study
  • Participants known to have a significant medical disease that would compromise their welfare or confound the study results
  • Participants with a history of or a current diagnosis of clinically significant portal hypertension
  • Participants who have a condition known to increase fecal fat loss including celiac's disease, biliary cancer, biliary stricture, cholelithiasis, Crohn's disease, pancreas cancer, radiation enteritis, tropical sprue, Whipple's disease, lactose intolerance, pseudomembranous colitis
  • Participants with a current diagnosis or a history of complete distal intestinal obstruction syndrome (DIOS) in the past 6 months; or, participants who had 2 or more episodes of DIOS in the past year
  • Participants with poorly controlled diabetes to the investigator's opinion
  • Female participants who are pregnant or lactating
  • Participants who received an investigational drug within 30 days prior to entry into the study
Both
7 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00408317
UMT20CF05-01
Yes
Aptalis Pharma
Aptalis Pharma
Not Provided
Study Director: Aptalis Medical Information Aptalis Pharma
Aptalis Pharma
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP